HRB Open Research

Ketamine as an adjunctive therapy for major depression - a randomised controlled pragmatic pilot trial (Karma-Dep Trial)

This first pragmatic randomised pilot trial of four once-weekly adjunctive ketamine infusions in hospitalised patients with major depression found the infusions were generally safe and well tolerated but produced no significant difference in HRSD-24 scores versus midazolam. The study indicates a definitive trial of adjunctive ketamine is feasible.

Published

January 27, 2022

Journal

HRB Open Research

Authors

Gallagher, B., Foley, M., Slattery, C. M., Gusciute, G., Shanahan, E., McLoughlin, D. M.